Celator Pharmaceuticals Secures $20Mmillion in Series D Funding Round
Celator Pharmaceuticals raised $20 million in a Series D private equity financing. The Princeton, N.J.-based cancer treatment developer plans to use proceeds to complete clinical trials and other efforts to advance its CPX-351 liposome injection as a treatment for acute myeloid leukemia. The latest funding round was led by a new investor, Thomas, McNerney & Partners. Previous investors (BDC Venture Capital, Domain Associates, GrowthWorks Capital, Quaker BioVentures, TL Ventures and Ventures West Capital) also participated.
1 September 2010•4 mins read
